Growing number of infectious diseases is expected to drive the growth of India streptomycin market during the forecast period.
INVC NEWS
Manhattan, NY,
According to TechSci Research report, “India Streptomycin Market By Source (In-house v/s Contract Manufacturing Organizations), By Form (Tablet, Capsule, Others), By Strength (100 mg, 200 mg, 300 mg, 400 mg, Others), By Distribution Channel (Online v/s Offline), By Application (Epilepsy, Neuropathic Pain, Restless Legs Syndrome (RLS), Seizures, Others), By End User (Adult v/s Paediatric), By Company, By Region, Forecast & Opportunities, FY2026”, the Indiastreptomycin market is expected to grow at a steady rate during the forecast period.World Health Organization has included streptomycinin the list of essential medicines that are safe and most effective medicines required in the healthcare system. Streptomycin is used to treat number of diseasessuch as tuberculosis, meningitis, throat Infection and so on. Thisis expected to fuel the market growth through FY2026. Furthermore, rising use of antibiotics in cell cultureis further projected to bode well for the market growth in the next 5 years. However, patent expiration and availability of substitute products are some of the impediments that can restrict the market growth over the next few years. Moreover,increasing resistance to antibiotics is another major concern which might further reduce the application of the drug thereby hindering the market growth during the forecast period.For instance, according to Centers for Disease Control and Prevention, it is estimated that around 2 million illnesses and 23,000 deaths occurs due to antibiotic resistance every year.
Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on “India Streptomycin Market”
The Indiastreptomycin market is segmented based on source, form, route of administration, type of manufacturing process, distribution channel, application, end user, company, and region. Based on end user, the market can be fragmented into adult v/s pediatric. The adult segment is forecasted to dominate the market during the forecast period. This dominance can be accredited to the wide use of streptomycinin adults to treat number of infectious diseases. Based on source, the market can be categorized into in-house v/s contract manufacturing organizations. The in-house segment dominated the market until FY2020 as most of the leading companies focus on in house production owing to high standardization and flexibility. Contract manufacturing organizations segment is expected to witness high growth in the market as it saves cost and maximize profits.
Macleods Pharmaceuticals Ltd., Abbott Healthcare Pvt Ltd. (AHPL), Hindustan Antibiotics Ltd. (HAL), Nestor Pharmaceuticals Ltd., Nitin Lifesciences Ltd., Wockhardt Limited, Neon Laboratories Ltd., Shalina Laboratories Pvt. Ltd., Wellona Pharma Pvt. Ltd., Cipla Ltd. and others are some of the leading players operating in India streptomycin market. Companies operating in the market are using strategies such as product launches, mergers and acquisitions and research collaborations to boost their share and increase their geographic reach.
“India streptomycin market is expected to witness growth during the forecast period owing torising use of antibiotics in cell culture. In addition to this, increasing awareness by various government and non-government organizations to control the bacterial infectious disease among peopleis further expected to create lucrative opportunities for the market growth of India streptomycinmarket in the forthcoming years. Growing number of antibiotic manufacturers coupled with presence of some of leading generics manufacturersin the country are some other major factors that are projected to bolster the market growth in the next 5 years.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based India management consulting firm.
“IndiaStreptomycin MarketBy Source (In-house v/s Contract Manufacturing Organizations), By Form (Tablet, Capsule, Others), By Strength (100 mg, 200 mg, 300 mg, 400 mg, Others), By Distribution Channel (Online v/s Offline), By Application (Epilepsy, Neuropathic Pain, Restless Legs Syndrome (RLS), Seizures, Others), By End User (Adult v/s Paediatric), By Company, By Region, Forecast & Opportunities, FY2026”, has evaluated the future growth potential of India streptomycin market and provides statistics &information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in India streptomycin
